stockrow10x Genomics
TXG Healthcare Medical Devices
10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.
- Revenue
- +1.12%
- EPS
- +31.8%
- Free cash flow
- −4.61%
Quarter to September 2026, against a year earlier
Follow TXG
Alert me
10x Genomics (TXG) Return on equity
10x Genomics's return on equity over the twelve months to 30 September 2026 was −8.27%, down 2.5 percentage points from fiscal 2025 (−5.78%). Over the past ten years it has ranged from −93.6% (fiscal 2020) to 67.6% (fiscal 2018); the current reading is higher than 78% of that period. That is above the Medical Devices industry median of −10.4% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −5.78% | 19.39 |
| FY2024 | −25.2% | 7.81 |
| FY2023 | −33.0% | (12.53) |
| FY2022 | −20.5% | (12.97) |
| FY2021 | −7.48% | 86.16 |
| FY2020 | −93.6% | (62.40) |
| FY2019 | −31.2% | (98.80) |
| FY2018 | 67.6% | 56.29 |
| FY2017 | 11.3% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| PODD Insulet Corporation compare | 28.9% |
| BIO.B Bio-Rad Laboratories, Inc. compare | 14.3% |
| BIO Bio-Rad Laboratories, Inc. compare | 14.3% |
| GMED Globus Medical, Inc. compare | 12.1% |
| HAE Haemonetics Corporation compare | 11.9% |
| PEN Penumbra, Inc. compare | 10.7% |
| SNN Smith & Nephew SNATS, Inc. compare | 0.00% |
| BRKR Bruker Corporation compare | −7.04% |
| TXG 10x Genomics | −9.40% |
| Medical Devices industry median | −10.4% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on TXG
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement